Loading...
Market
Will the FDA approve a new GLP-1 drug for reducing cancer risk in Type 2 diabetes patients by the end of 2024?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
FDA announcements and official press releases
Story
Study Finds Ozempic, Wegovy Lower Cancer Risk in Type 2 Diabetes Patients by 10 out of 13
Jul 5, 2024, 05:09 PM
A new study has found that GLP-1 drugs, including Ozempic and Wegovy, significantly reduce the risk of cancer in patients with type 2 diabetes. The retrospective cohort study, which analyzed electronic health records of approximately 1.65 million people over 15 years, revealed that patients on GLP-1 medications had a lower risk for 10 out of 13 obesity-related cancers compared to those on insulin therapy. The findings, published Friday in JAMA Network Open, were based on data from 113 million US patients and suggest a promising alternative for reducing cancer risk in diabetic patients.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Approved for all indications • 25%
Approved for some indications • 25%
Not approved • 25%
Approval delayed • 25%
Yes • 50%
No • 50%
